Sera Prognostics, Inc. Stock Price, News & Analysis

Sera Prognostics Inc. (NASDAQ: SERA), known as The Pregnancy Company®, has announced its plans to report second quarter fiscal year 2024 financial results on August 7, 2024, after market close. The company, which focuses on improving maternal and neonatal health through innovative pregnancy biomarker information, will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day.

The event will cover operational highlights, financial results, and key topics. Investors and interested parties can access the call via phone or webcast. US domestic callers should use (800) 836-8184, while international callers can dial (646) 357-8785. The webcast registration link is provided, and live audio will be available on the company's website. The webcast will be archived for one year on the Investors page.

Sera Prognostics has announced that their PreTRM® test-and-treat strategy has demonstrated significant improvements in neonatal health outcomes, as reported in the international journal Diagnostics. The AVERT PRETERM TRIAL showed an 18% reduction in severe neonatal morbidity and mortality, a 7-day reduction in the average hospital stay for neonates, a 2.48-week increase in gestational age for births before 32 weeks, and a 28-day reduction in hospital stays for neonates born before 32 weeks. These findings are significant for improving neonatal health in pregnancies previously considered low-risk. Additionally, the Data Safety and Monitoring Board has recommended stopping enrollment in the PRIME study due to meeting efficacy endpoints. Final results from this study are currently being analyzed.

Sera Prognostics (Nasdaq: SERA) has been added to the Russell 2000 and 3000 indexes following the 2024 annual reconstitution finalized on June 28, 2024. Effective today, the company joins the list of the 4,000 largest US stocks ranked by market capitalization as of April 30, 2024. Membership in the Russell 3000 Index entails automatic inclusion in the Russell 1000 or Russell 2000 indexes, along with relevant growth and value style indexes. The Russell indexes are significant benchmarks, used by investment managers and institutional investors, with $10.5 trillion in assets benchmarked as of December 2023. This inclusion marks a notable milestone for Sera Prognostics, enhancing its visibility among key financial stakeholders.

Sera Prognostics, specializing in maternal and neonatal health, announced its inclusion in the preliminary list for the Russell 2000 and Russell 3000 indexes. The Russell indexes, managed by FTSE Russell, include the top 4,000 US stocks based on market capitalization as of April 30, 2024. This inclusion is for one year and will give Sera exposure to investment managers and institutional investors who use these indexes as benchmarks, involving about $10.5 trillion in assets. Sera's President and CEO, Zhenya Lindgardt, sees this as a significant milestone in the company’s mission to enhance pregnancy-related healthcare.

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), reported its first-quarter 2024 financial results, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information. The company highlighted submitting PRIME study interim analysis results for publication, launching ambient whole blood collection kits to reduce costs and increase lab processing efficiency, and expanding into international markets. Despite revenue adjustments, operational expenses decreased, resulting in a narrower net loss compared to the same quarter in 2023.

Sera Prognostics Inc., a company focused on improving maternal and neonatal health, will report first quarter fiscal year 2024 financial results on May 8, 2024. The conference call and webcast will discuss operational highlights, financial results, and key topics at 5:00 p.m. Eastern Time. Details for the call are provided for both US domestic and international callers.